Vapogenix, Inc., a Houston, Texas-based developer of non-opioid medicine for localized pain, raised $8.2m in funding.
Pamoja Capital, prominent pain physicians and others invested in the round.
Vapogenix develops a topical, non-opioid medicine for localized pain,
The company intends to use the funds to begin a Phase 2 Proof-of-Concept study for Project AWARD (A Wound Analgesic with RapiD action) in 2017.
Led by Danguole Altman, CEO and Co-Founder, and Allen Burton, MD, Co-Founder and Scientific Advisory Board Chairman, Vapogenix is advancing a locally-acting analgesic based on volatile anesthetics (VAs).
The company has formulated these VAs into topical gels and liquids and intends to treat various painful conditions including wounds, combat-related injuries, osteoarthritis, muscular and inflammatory conditions.
FinSMEs
08/12/2016